ClinicalTrials.gov posted results on 26 August 2026 from a completed Phase 2 study of deucravacitinib in pityriasis rubra pilaris. The seven-participant study reported a mean reduction of 51.5 percentage points in total body surface area affected, with a standard deviation of 36.1.

Background

The trial evaluated deucravacitinib, also identified in the record as BMS-986165, for pityriasis rubra pilaris. The study assessed safety and effectiveness using Investigator Global Assessment, PASI response thresholds, the Dermatology Life Quality Index, itch measured by a numeric rating scale, and Skindex-16. It also aimed to identify potential biomarkers of pityriasis rubra pilaris using single-cell RNA sequencing.

Trial design

This was a completed Phase 2 trial enrolling 7 participants with pityriasis rubra pilaris. The registered intervention was deucravacitinib. The planned assessments were made at week 24, but the supplied record did not list primary outcome entries or identify a comparator arm.

Key results

Mean PASI scores changed by -22.2 score points, with a standard deviation of 12.9. Patient-reported itch changed by a mean of -3.2 score points, with a standard deviation of 2.9. The mean change in DLQI was -12.7 score points, with a standard deviation of 10.0, while Skindex-16 changed by -36.2 score points, with a standard deviation of 29.4.

  • 4 participants were reported as responsive to treatment based on Physician Global Assessment.
  • Total affected body surface area changed by a mean of -51.5 percentage points, with a standard deviation of 36.1.
  • Four regional body-surface-area measurements changed by means of -4.7, -9.1, -15.6, and -22.2 percentage points. Their standard deviations were 4.1, 8.1, 14.4, and 12.3, respectively.

The record also listed Wilcoxon (Mann-Whitney) analyses with p-values of 0.031, 0.098, 0.063, 0.063, 0.063, and 0.106. The supplied data did not link most of these analyses to specific outcomes; the final analysis was identified as concerning head BSA.

What this means

In this small completed study, deucravacitinib was associated with reported reductions in affected skin area, itch, and dermatology quality-of-life scores at the recorded assessment. The sample included only seven participants, and the supplied record did not provide primary outcome entries, an adverse-event summary, or a comparator description. These results therefore do not establish comparative efficacy, comparative safety, or a new approval.

Source

Source: ClinicalTrials.gov, trial-results record for NCT06444399, posted 26 August 2026. The registry record is available at clinicaltrials.gov/study/NCT06444399.